Correlations between no observed effect level and selected parameters of the chemical structure for veterinary drugs

Toxicology in Vitro

Volumn 24, Issue 3, 2010, Pages 953-959

  Grabowski, Tomasz ^a   Jaroszewski, Jerzy Jan ^b   Piotrowski, Walerian ^c  

^a FILAB   (Poland)

^b UNIVERSITY OF WARMIA AND MAZURY IN OLSZTYN   (Poland)

^c INSTITUTE OF CARDIOLOGY   (Poland)

Author keywords

In silico; LogKOW; LogSw; NOEL; PSA

Indexed keywords

APRAMYCIN; AVILAMYCIN; BACITRACIN; BETAMETHASONE; CEFAPIRIN; CEFTIOFUR; CLAVULANIC ACID; COLISTIN; DANOFLOXACIN; DEXAMETHASONE; DIFLOXACIN; ENROFLOXACIN; FEBANTEL; FLORFENICOL; FURAZOLIDONE; FUROSEMIDE; ISOXSUPRINE; LINCOMYCIN; MARBOFLOXACIN; MELOXICAM; NATAMYCIN; NEOMYCIN; OMEPRAZOLE; OXFENDAZOLE; PARACETAMOL; PAROMOMYCIN; PREDNISOLONE; STREPTOMYCIN; UNINDEXED DRUG; VETERINARY DRUG;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SAFETY; DRUG STRUCTURE; HYDROGEN BOND; PARTITION COEFFICIENT; SOLUBILITY;

COMPUTER SIMULATION; HYDROGEN BONDING; NO-OBSERVED-ADVERSE-EFFECT LEVEL; SOFTWARE; SOLUBILITY; SOLVENTS; STRUCTURE-ACTIVITY RELATIONSHIP; SURFACE PROPERTIES; VETERINARY DRUGS;

EID: 77649341203     PISSN: 08872333     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tiv.2010.01.003     Document Type: Article

References (39)

1. Abraham M.H., Ibrahim A., Zissimos A.M., Zhao Y.H., Comer J., and Reynolds D.P. Application of hydrogen bonding calculations in property based drug design. Drug Discov. Today 20 (2002) 1056-1063
2. Anderson M.E., and Barton H.A. The use of biochemical and molecular parameters to estimate dose-response relationships at low levels of exposure. Environ. Health Perspect. 106 (1998) 349-355
3. Benford D. The acceptable daily intake a tool for ensuring food safety. ILSI Europe (2000) 1-38
4. Bonora E., Willeit J., Kiechl S., Oberhollenzer F., Egger G., Bonadonna R., and Muggeo M. Relationship between insulin and carotid atherosclerosis in the general population. The Bruneck Study. Stroke 6 (1997) 1147-1152
5. Broto P., Moreau G., and VanDycke C. Molecular structures: perception, autocorrelation descriptor and QSAR studies. System of atomic contributions for the calculation of the n-octanol/water coefficients. Eur. J. Med. Chem. 19 (1984) 71-78
6. Clark D.E. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption. J. Pharm. Sci. 88 (1999) 807-814
7. Contrera J.F., Matthews E.J., Kruhlak N.L., and Benz R.D. Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose. Regul. Toxicol. Pharmacol. 40 (2004) 185-206
8. Contrera J.F., Maclaughlin P., Hall L.H., and Kier L.B. QSAR modeling of carcinogenic risk using discriminant analysis and topological molecular descriptors. Curr. Drug Discov. Technol. 2 (2005) 55-67
9. De Simone A., Esposito L., Pedone C., and Vitagliano L. Insights into stability and toxicity of amyloid-like oligomers by replica exchange molecular dynamics analyses. Biophys. J. 4 (2008) 1965-1973
10. Dourson M., and Barnes D.G. Reference dose (RfD): description and use in health risk assessment. Regul. Toxicol. Pharmacol. 8 (1988) 471-486
11. EMEA, 2005. Comments on JECFA/Codex Alimentarius Statistical Methods for the Estimation of MRLs. EMEA, pp. 1-2.
12. EMEA, 2008. Veterinary Medicines - Maximum Residue Limits (MRL), Summary Reports and EPMARs. .
13. Farrar V.A., Ciechanowicz-Rutkowska M., Grochowski J., Serda P., Pilati T., Filippini G., Hinko C.N., El-Assadi A., Moore J.A., Edafiogho I.O., Andrews C.W., Cory M., Nicholson J.M., and Scott K.R. Synthesis and CLOGKOW correlation of imidooxy anticonvulsants. J. Med. Chem. 36 (1993) 3517-3525
14. US FDA, 2004. Assessment of the Effects of Antimicrobial Drug Residues from Food of Animal Origin on the Human Intestinal Flora. FDA, pp. 3-8.
15. Grellier P., Nemeikaite-Ceniene A., Sarlauskas J., and Cenas N. Role of single-electron oxidation potential and lipophilicity in the antiplasmodial in vitro activity of polyphenols: comparison to mammalian cells. Z. Naturforsch. C 63 (2008) 445-450
16. Henderson R.F., Bechtold W.E., Medinsky M.A., Fischer J.P., and Lee T.T. The effect of molecular weight/lipophilicity on clearance of organic compounds from lungs. Toxicol. Appl. Pharmacol. 3 (1988) 515-521
17. R.C. Hertzberg, M.L. Dourson, 1993. Using categorical regression instead of a NOAEL to characterize a toxicologist's judgment in noncancer risk assessment. In: Ayyub, B.M. (Ed.), Proceedings of the Second International Symposium on Uncertainty Modeling and Analysis, College Park, MD. IEEE Computer Society Press, Los Alamitos, pp. 254-261.
18. Hollósy F., Lóránd T., Orfi L., Erös D., Kéri G., and Idei M. Relationship between lipophilicity and antitumor activity of molecule library of Mannich ketones determined by high-performance liquid chromatography. CLogKOW calculation and cytotoxicity test. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2 (2002) 361-368
19. Lipinski C.A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Meth. 44 (2000) 235-249
20. Lipinski C.A. Single-mode compound retrieval for QSAR, QSPR data sets, and batch mode exact structure searching. J. Pharm. Sci. 91 (2002) 2470-2472
21. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46 (2001) 3-26
22. Lobell M., and Sivarajah V. In silico prediction of aqueous solubility, human plasma protein binding and volume of distribution of compounds from calculated pKa and ALogKOW98 values. Mol Divers. 1 (2003) 69-87
23. Machatha S.G., and Yalkowsky S.H. Comparison of the octanol/water partition coefficients calculated by ClogP, ACDlogP and KowWin to experimentally determined values. Int. J. Pharm. 294 (2005) 185-192
24. Matthews E.J., and Contrera J.F. In silico approaches to explore toxicity end points: issues and concerns for estimating human health effects. Expert Opin. Drug Metab. Toxicol. 1 (2007) 125-134
25. Matthews E.J., Kruhlak N.L., Benz R.D., and Contrera J.F. Assessment of the health effects of chemicals in humans: I. QSAR estimation of the maximum recommended therapeutic dose (MRTD) and no effect level (NOEL) of organic chemicals based on clinical trial data. Curr. Drug Discov. Technol. 1 (2004) 61-76
26. Matthews E.J., Kruhlak N.L., Benz R.D., and Contrera J.F. A comprehensive model for reproductive and developmental toxicity hazard identification: I. development of a weight of evidence QSAR database. Regul. Toxicol. Pharmacol. 2 (2007) 115-135
27. Mattisson I., Wirfält E., Andrén C., Gullberg B., and Berglund G. Dietary fat intake-food sources and dietary correlates in the Malmö Diet and Cancer cohort. Public Health Nutr. 6 (2003) 559-569
28. Mumtaz M.M., Knauf L.A., Reisman D.J., Peirano W.B., DeRosa C.T., Gombar V.K., Enslein K., Carter J.R., Blake B.W., Huque K.I., and Ramanujam V.M.S. Assessment of effect levels of chemicals from quantitative structure-activity relationship (QSAR) models. I. Chronic lowest-observed-adverse-effect level (LOAEL). Toxicol. Lett. 79 (1995) 131-143
29. Neighbors J.D., Salnikova M.S., Beutler J.A., and Wiemer D.F. Synthesis and structure-activity studies of schweinfurthin B analogs: evidence for the importance of a D-ring hydrogen bond donor in expression of differential cytotoxicity. Bioorg. Med. Chem. 6 (2006) 1771-1784
30. Netwig G. Effects of pharmaceuticals on aquatic invertebrates. Part II: the antidepressant drug fluoxetine. Arch. Environ. Contam. Toxicol. 52 (2007) 163-170
31. Oprea T.I. Current trends in lead discovery: are we looking for the appropriate properties?. J. Comput. Aid. Mol. Des. 16 (2002) 325-334
32. Parker M.A., Kurrasch D.M., and Nichols D.E. The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands. Bioorg. Med. Chem. 16 (2008) 4661-4669
33. Pedretti A., Villa L., and Vistoli G. VEGA: a versatile program to convert, handle and visualize molecular structure on Windows-based PCs. J. Mol. Graph. Model. 21 (2002) 47-49
34. Pedretti A., Villa L., and Vistoli G. VEGA - an open platform to develop chemo-bio-informatics applications. Using plug-in architecture and script programming. J. Comput. Aid. Mol. Des. 18 (2004) 167-173
35. Truong D.M., Kaler G., Khandelwal A., Swaan P.W., and Nigam S.K. Multi-level analysis of organic anion transporters 1, 3, and 6 reveals major differences in structural determinants of antiviral discrimination. J. Biol. Chem. 13 (2008) 8654-8663
36. Venkatapathy R., Moudgal C.J., and Bruce R.M. Assessment of the oral rat chronic lowest observed adverse effect level model in TOPKAT, a QSAR software package for toxicity prediction. J. Chem. Inf. Comput. Sci. 5 (2004) 1623-1629
37. WHO, 2004. Joint FAO/WHO Technical Workshop on Residues of Veterinary Drugs without ADI/MRL, FAO, WHO, pp. 3-16.
38. Winchester J.F., and Audia P.F. Extracorporeal strategies for the removal of middle molecules. Semin. Dial. 2 (2006) 110-114
39. Witte I., Jacobi H., and Juhl-Strauss U. Correlation of synergistic cytotoxic effects of environmental chemicals in human fibroblasts with their lipophilicity. Chemosphere 31 (1995) 4041-4049